CAR T-cell therapy is a type of Adoptive Cell Therapy – one of the approaches to immunotherapy. The therapy uses a patient’s own white blood cells, modifies them in a lab and retrains them to recognize specific markers on the surface of the cell. The modified cells are infused back in to the patient where they target and kill only those cancerous cells. Through clinical trials CAR T has been proven to work quickly and often has fewer side effects than traditional cancer treatments like chemotherapy and radiation. Patients have described feeling the cells attack their cancer almost immediately after the infusion, and many have experienced complete remission in a few months.
Currently the Food and Drug Administration (FDA) has approved two CAR T-cell drugs. Yescarta®, a Kite product, is approved for adults with advanced non-Hodgkins lymphoma. Kymriah™, a Novartis product, is available for children and young adults with a rare type of treatment-resistant childhood leukemia. Kymriah was also recently approved by the FDA for adults with advanced non-Hodgkins lymphoma.
The OSUCCC – James was the first cancer treatment center in Ohio and one of only a few nationwide to offer this new therapy for adults and young adults. In addition to these therapies, the OSUCCC – James has a number of CAR T-cell therapy clinical trials on going.
If you’ve been diagnosed with cancer, would like a second opinion or would like to speak with a cancer specialist, please call The James Line at 800-293-5066 or 614-293-5066 to make an appointment.